CellBion seeks conditional approval for prostate cancer treatment candidate 177Lu-pocuvotide

Alphamab Oncology announces IND application for a Phase 3 clinical study of HER2 bispecific ADC...

Junshi Biosciences EGFR-HER3 bispecific antibody ADC has successfully advanced to its global Phase 2 clinical...

Senhwa Biosciences aims at multi-billion dollar global market with CX-5461 combined with ADC “blockbuster” therapy

Harbour BioMed enters into long-term strategic collaboration with Lannacheng to advance next-generation radionuclide drug conjugates

BioAtla and GATC health announce a $40 million special purpose vehicle (SPV) transaction to advance...